InMed Pharma raises $5M in private placement of pre-funded warrants and options

InMed Pharmaceuticals Inc.

Gross proceeds ~$5M from 1,952,363 pre-funded warrants ($0.0001 exercise) and 1,952,363 preferred investment options at $2.436/share.
Amended 199,115 existing options (Oct 2023) from $16.60 to $2.436 per share for $0.125 each.
Proceeds to fund pipeline development, BayMedica commercial sales, and working capital.
H.C. Wainwright acted as placement agent; received 126,904 agent options at $3.2013/share.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.